Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL
/in Dendritic Cells, International Publications /von 2009-09-08 / Mol. Ther. 2010 Feb;18(2):264-74Harnessing dendritic cells to generate cancer vaccines
/in Dendritic Cells, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:88-98Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
/in Dendritic Cells, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:41-50Brain tumor immunotherapy with type-1 polarizing strategies
/in Glioblastoma, International Publications /von 2009-09-01 / Ann. N. Y. Acad. Sci. 2009 Sep;1174:18-23Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International Publications /von 2009-09-01 / Int. J. Oncol. 2009 Sep;35(3):569-81Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2009-09-01 / Prostate 2009 Sep;69(12):1343-52Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2009-08-08 / Med. Oncol. 2010 Sep;27(3):736-42Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
/in Dendritic Cells, Glioblastoma, International Publications /von 2009-08-01 / Stem Cells 2009 Aug;27(8):1734-40IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de